๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Transient focal leukoencephalopathy following intraventricular methotrexate and cytarabine

โœ Scribed by V. Colamaria; R. Caraballo; C. Borgna-Pignatti; P. Marradi; R. Balter; C. Mazza; C. Procacci; B. Dalla Bernardina

Book ID
105328074
Publisher
Springer
Year
1990
Tongue
English
Weight
505 KB
Volume
6
Category
Article
ISSN
0256-7040

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Transient encephalopathy following high-
Transient encephalopathy following high-dose methotrexate
โœ Lee, Anselm C.W. ;Li, C.H. ;Wong, Y.C. ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 31 KB

## CORRESPONDENCE Transient Encephalopathy Following High-Dose Methotrexate Sir: Methotrexate can cause acute neurotoxicity characterized by confusion, disorientation, seizures, and focal neurologic deficits [1]. We read with interest the brief report by Peyriere et al. [2] of transient encephalop

Intraventricular concentration times tim
Intraventricular concentration times time (C ร— T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma
โœ Asher M. Moser; Peter C. Adamson; Andrea J. Gillespie; David G. Poplack; Frank M ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 94 KB

## Background: Intraventricular chemotherapy results in more uniform drug distribution within the subarachnoid space and allows for more flexible drug administration schedules. the authors report their experience with an intraventricular concentration times time (c x t) chemotherapy regimen for rec

Transient neurologic dysfunction followi
Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma
โœ Roy L. Martino; Al B. Benson III; James A. Merritt; Jeffrey J. Brown; John R. Le ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 299 KB ๐Ÿ‘ 1 views

Two patients, aged 24 and 19 years, who had undifferentiated lymphoma, developed the acute onset of focal neurologic deficits 10 days after treatment with moderate-dose methotrexate (2.76 g/m2 by 42-hour intravenous infusion) and 12.5 mg of intrathecal methotrexate. Prior chemotherapy also included